These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 34518053)

  • 1. Pelvic exenteration for recurrent or persistent gynecologic malignancies: Clinical and histopathologic factors predicting recurrence and survival in a modern cohort.
    Straubhar AM; Chi AJ; Zhou QC; Iasonos A; Filippova OT; Leitao MM; Awowole IO; Abu-Rustum NR; Broach VA; Jewell EL; Sandhu JS; Sonoda Y
    Gynecol Oncol; 2021 Nov; 163(2):294-298. PubMed ID: 34518053
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pelvic exenteration for recurrent gynecologic malignancy: a study of 28 consecutive patients at a single institution.
    Jäger L; Nilsson PJ; Rådestad AF
    Int J Gynecol Cancer; 2013 May; 23(4):755-62. PubMed ID: 23407096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Overall survival after pelvic exenteration for gynecologic malignancy.
    Westin SN; Rallapalli V; Fellman B; Urbauer DL; Pal N; Frumovitz MM; Ramondetta LM; Bodurka DC; Ramirez PT; Soliman PT
    Gynecol Oncol; 2014 Sep; 134(3):546-51. PubMed ID: 25014540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pelvic exenteration for gynecologic malignancies: The experience of a tertiary center from Greece.
    Haidopoulos D; Pergialiotis V; Aggelou K; Thomakos N; Alexakis N; Stamatakis E; Rodolakis A
    Surg Oncol; 2022 Mar; 40():101702. PubMed ID: 35065392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pelvic exenteration for recurrent squamous cell carcinoma of the pelvic organs arising from the cloaca--a single institution's experience over 16 years.
    Tan KK; Pal S; Lee PJ; Rodwell L; Solomon MJ
    Colorectal Dis; 2013; 15(10):1227-31. PubMed ID: 23714581
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pelvic Exenteration in Advanced Gynecologic Malignancies - Who Will Benefit?
    Egger EK; Liesenfeld H; Stope MB; Recker F; Döser A; Könsgen D; Marinova M; Hilbert T; Exner D; Ellinger J; Mustea A
    Anticancer Res; 2021 Jun; 41(6):3037-3043. PubMed ID: 34083295
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pelvic exenteration as ultimate ratio for gynecologic cancers: single-center analyses of 37 cases.
    de Gregorio N; de Gregorio A; Ebner F; Friedl TWP; Huober J; Hefty R; Wittau M; Janni W; Widschwendter P
    Arch Gynecol Obstet; 2019 Jul; 300(1):161-168. PubMed ID: 31011878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pelvic exenterations for gynecological malignancies: a study of 36 cases.
    Kaur M; Joniau S; D'Hoore A; Van Calster B; Van Limbergen E; Leunen K; Penninckx F; Van Poppel H; Amant F; Vergote I
    Int J Gynecol Cancer; 2012 Jun; 22(5):889-96. PubMed ID: 22617477
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of tumor size on outcomes following pelvic exenteration.
    Smith B; Jones EL; Kitano M; Gleisner AL; Lyell NJ; Cheng G; McCarter MD; Abdel-Misih S; Backes FJ
    Gynecol Oncol; 2017 Nov; 147(2):345-350. PubMed ID: 28822555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pelvic Exenteration in Gynecologic Cancer: La Paz University Hospital Experience.
    Moreno-Palacios E; Diestro MD; De Santiago J; Hernández A; Zapardiel I
    Int J Gynecol Cancer; 2015 Jul; 25(6):1109-14. PubMed ID: 25853383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors for long-term survival after interdisciplinary salvage surgery for advanced or recurrent gynecologic cancers.
    Fleisch MC; Pantke P; Beckmann MW; Schnuerch HG; Ackermann R; Grimm MO; Bender HG; Dall P
    J Surg Oncol; 2007 May; 95(6):476-84. PubMed ID: 17192947
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of pelvic exenteration for gynecologic malignancies.
    Moolenaar LR; van Rangelrooij LE; van Poelgeest MIE; van Beurden M; van Driel WJ; van Lonkhuijzen LRCW; Mom CH; Zaal A
    Gynecol Oncol; 2023 Apr; 171():114-120. PubMed ID: 36870097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic factors in pelvic exenteration for gynecological malignancies.
    Baiocchi G; Guimaraes GC; Rosa Oliveira RA; Kumagai LY; Faloppa CC; Aguiar S; Begnami MD; Soares FA; Lopes A
    Eur J Surg Oncol; 2012 Oct; 38(10):948-54. PubMed ID: 22818842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration.
    Donati OF; Lakhman Y; Sala E; Burger IA; Vargas HA; Goldman DA; Andikyan V; Park KJ; Chi DS; Hricak H
    Eur Radiol; 2013 Oct; 23(10):2906-15. PubMed ID: 23652852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does intra-operative radiation at the time of pelvic exenteration improve survival for patients with recurrent, previously irradiated cervical, vaginal, or vulvar cancer?
    Backes FJ; Billingsley CC; Martin DD; Tierney BJ; Eisenhauer EL; Cohn DE; O'Malley DM; Salani R; Copeland LJ; Fowler JM
    Gynecol Oncol; 2014 Oct; 135(1):95-9. PubMed ID: 25084510
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration.
    Burger IA; Vargas HA; Donati OF; Andikyan V; Sala E; Gonen M; Goldman DA; Chi DS; Schöder H; Hricak H
    Gynecol Oncol; 2013 Jun; 129(3):586-592. PubMed ID: 23369941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesorectal lymph node involvement and prognostic implications at total pelvic exenteration for gynecologic malignancies.
    Mourton SM; Chi DS; Sonoda Y; Alektiar KM; Venkatraman ES; Barakat RR; Abu-Rustum NR
    Gynecol Oncol; 2006 Mar; 100(3):533-6. PubMed ID: 16226800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The influence of surgeon volume on outcomes after pelvic exenteration for a gynecologic cancer.
    Jalloul RJ; Nick AM; Munsell MF; Westin SN; Ramirez PT; Frumovitz M; Soliman PT
    J Gynecol Oncol; 2018 Sep; 29(5):e68. PubMed ID: 30022632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Performance and outcome of pelvic exenteration for gynecologic malignancies: A population-based study.
    Matsuo K; Mandelbaum RS; Adams CL; Roman LD; Wright JD
    Gynecol Oncol; 2019 May; 153(2):368-375. PubMed ID: 30792003
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Feasibility of adjuvant chemotherapy after pelvic exenteration for gynecologic malignancies.
    Andikyan V; Khoury-Collado F; Sandadi S; Tew WP; O'Cearbhaill RE; Konner JA; Sonoda Y; Barakat RR; Chi DS; Abu-Rustum NR
    Int J Gynecol Cancer; 2013 Jun; 23(5):923-8. PubMed ID: 23698798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.